Literature DB >> 7669103

Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase.

M J During1, J R Naegele, K L O'Malley, A I Geller.   

Abstract

One therapeutic approach to treating Parkinson's disease is to convert endogenous striatal cells into levo-3,4-dihydroxyphenylalanine (L-dopa)-producing cells. A defective herpes simplex virus type 1 vector expressing human tyrosine hydroxylase was delivered into the partially denervated striatum of 6-hydroxydopamine-lesioned rats, used as a model of Parkinson's disease. Efficient behavioral and biochemical recovery was maintained for 1 year after gene transfer. Biochemical recovery included increases in both striatal tyrosine hydroxylase enzyme activity and in extracellular dopamine concentrations. Persistence of human tyrosine hydroxylase was revealed by expression of RNA and immunoreactivity.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7669103      PMCID： PMC2638002          DOI： 10.1126/science.266.5189.1399

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  50 in total

1.  A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons.

Authors:  A T Dobson; T P Margolis; F Sedarati; J G Stevens; L T Feldman
Journal:  Neuron       Date:  1990-09       Impact factor: 17.173

2.  Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1.

Authors:  D J McGeoch; A Dolan; S Donald; D H Brauer
Journal:  Nucleic Acids Res       Date:  1986-02-25       Impact factor: 16.971

3.  Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

Authors:  J A Wolff; L J Fisher; L Xu; H A Jinnah; P J Langlais; P M Iuvone; K L O'Malley; M B Rosenberg; S Shimohama; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

5.  Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5' alternative splice sites responsible for multiple mRNAs.

Authors:  K L O'Malley; M J Anhalt; B M Martin; J R Kelsoe; S L Winfield; E I Ginns
Journal:  Biochemistry       Date:  1987-11-03       Impact factor: 3.162

6.  A protein tyrosine phosphatase expressed within dopaminoceptive neurons of the basal ganglia and related structures.

Authors:  P J Lombroso; J R Naegele; E Sharma; M Lerner
Journal:  J Neurosci       Date:  1993-07       Impact factor: 6.167

7.  The nucleotide sequence of a rat 18 S ribosomal ribonucleic acid gene and a proposal for the secondary structure of 18 S ribosomal ribonucleic acid.

Authors:  Y L Chan; R Gutell; H F Noller; I G Wool
Journal:  J Biol Chem       Date:  1984-01-10       Impact factor: 5.157

8.  Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: long-term behavioral, biochemical, and histochemical studies.

Authors:  W J Freed; M J Perlow; F Karoum; A Seiger; L Olson; B J Hoffer; R J Wyatt
Journal:  Ann Neurol       Date:  1980-11       Impact factor: 10.422

9.  An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-dopa from cultured rat striatal cells.

Authors:  A I Geller; M J During; Y J Oh; A Freese; K O'Malley
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

10.  Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine.

Authors:  D E Redmond; J R Sladek; R H Roth; T J Collier; J D Elsworth; A Y Deutch; S Haber
Journal:  Lancet       Date:  1986-05-17       Impact factor: 79.321
View more
  49 in total

Review 1.  Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system.

Authors:  D S Latchman
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

2.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

3.  Sparing of neuronal function postseizure with gene therapy.

Authors:  J McLaughlin; B Roozendaal; T Dumas; A Gupta; O Ajilore; J Hsieh; D Ho; M Lawrence; J L McGaugh; R Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

4.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

Review 5.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 6.  Neurovirological methods and their applications.

Authors:  P G E Kennedy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

7.  Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.

Authors:  Mei Sun; Guo-Rong Zhang; Lingxin Kong; Courtney Holmes; Xiaodan Wang; Wei Zhang; David S Goldstein; Alfred I Geller
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

Review 8.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

9.  Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts.

Authors:  C Bencsics; S R Wachtel; S Milstien; K Hatakeyama; J B Becker; U J Kang
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

Review 10.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.